HUP0301551A2 - 5-HT3 és idegi nikotinsav receptor antagonista 1-amino-alkil-ciklohexán származékok új alkalmazása - Google Patents

5-HT3 és idegi nikotinsav receptor antagonista 1-amino-alkil-ciklohexán származékok új alkalmazása

Info

Publication number
HUP0301551A2
HUP0301551A2 HU0301551A HUP0301551A HUP0301551A2 HU P0301551 A2 HUP0301551 A2 HU P0301551A2 HU 0301551 A HU0301551 A HU 0301551A HU P0301551 A HUP0301551 A HU P0301551A HU P0301551 A2 HUP0301551 A2 HU P0301551A2
Authority
HU
Hungary
Prior art keywords
general formula
nicotinicreceptor
alkycyclohexanes
neuronal
antagonist
Prior art date
Application number
HU0301551A
Other languages
English (en)
Inventor
Wojciech Danysz
Markus Gold
Aigars Jirgensons
Ivars Kalvinsh
Valerjans Kauss
Christopher Graham Raphael Parsons
Original Assignee
Merz Pharma Gmbh & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co. Kgaa filed Critical Merz Pharma Gmbh & Co. Kgaa
Publication of HUP0301551A2 publication Critical patent/HUP0301551A2/hu
Publication of HUP0301551A3 publication Critical patent/HUP0301551A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány 1-amino-alkil-ciklohexán-származékok új alkalmazásairavonatkozik. A találmány az (I) általános képletű 1-amino-alkil-ciklohexán-származékoknak ahol R* jelentése -(CH2)n-(CR6R7)m-NR8R9általános képletű csoport, ahol n+m értéke 0, 1 vagy 2; R1- R7jelentése egymástól függetlenül hidrogénatom vagy (1-6 szénatomos) kisszénatomszárnú alkilcsoport, R8 és R9 jelentése hidrogénatom vagy (1-6szénatomos) kis szénatomszámú alkilcsoport, vagy közösen -(CH2)xáltalános képletű kis szénatomszámú alkiléncsoportot képezhetnek, aholx értéke 2-5; valamint enantiomerjeinek, optikai izomerjeinek,hidrátjainak vagy gyógyászatilag elfogadható sóinak új alkalmazására,az alkalmazásukkal előállítható gyógyszerkészítményekre vonatkozik,amelyekkel egy élő állatot kezelve az állat erre reagáló állapotátenyhíthetik. Ó
HU0301551A 2000-06-20 2001-06-19 New use of 5ht3 and neuronal nicotinicreceptor antagonist 1-amino-alkycyclohexanes HUP0301551A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59710200A 2000-06-20 2000-06-20
PCT/EP2001/006964 WO2001098253A2 (en) 2000-06-20 2001-06-19 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists

Publications (2)

Publication Number Publication Date
HUP0301551A2 true HUP0301551A2 (hu) 2003-11-28
HUP0301551A3 HUP0301551A3 (en) 2005-04-28

Family

ID=24390098

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301551A HUP0301551A3 (en) 2000-06-20 2001-06-19 New use of 5ht3 and neuronal nicotinicreceptor antagonist 1-amino-alkycyclohexanes

Country Status (21)

Country Link
US (2) US20070105961A1 (hu)
EP (2) EP1303477A2 (hu)
JP (1) JP4159351B2 (hu)
KR (1) KR100570374B1 (hu)
CN (1) CN1307147C (hu)
AR (1) AR032756A1 (hu)
AU (2) AU2001281861B2 (hu)
CA (1) CA2410852C (hu)
CZ (1) CZ2003497A3 (hu)
EA (1) EA006067B1 (hu)
GE (1) GEP20053431B (hu)
HK (1) HK1076276A1 (hu)
HU (1) HUP0301551A3 (hu)
IL (2) IL153480A0 (hu)
MX (1) MXPA02012244A (hu)
NO (1) NO329491B1 (hu)
PL (1) PL359583A1 (hu)
TW (1) TW593223B (hu)
UA (1) UA74194C2 (hu)
WO (1) WO2001098253A2 (hu)
ZA (1) ZA200104187B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
EP1556019A2 (en) * 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2005000216A2 (en) 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
WO2005009421A2 (en) * 2003-07-28 2005-02-03 Merz Pharma Gmbh & Co. Kgaa The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
CN101389315A (zh) * 2004-06-17 2009-03-18 莫茨药物股份两合公司 美金刚口服剂型即释制剂
JP2008527035A (ja) * 2005-01-18 2008-07-24 ユニヴァーシテイ オブ フロリダ 疼痛を抑制するための組成物及び方法
DK2540297T3 (en) 2008-11-19 2015-07-13 Forum Pharmaceuticals Inc The treatment of cognitive disorders with (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
AU2009328497A1 (en) 2008-12-19 2010-06-24 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
BR112012029237A2 (pt) 2010-05-17 2016-11-29 Envivo Pharmaceuticals Inc forma cristalina de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida monohidratado
RU2635522C2 (ru) 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
US5886051A (en) * 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
TW593225B (en) * 1997-06-30 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane NMDA receptor antagonists
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Also Published As

Publication number Publication date
AU2001281861B2 (en) 2006-08-17
WO2001098253A2 (en) 2001-12-27
EP2277850A1 (en) 2011-01-26
ZA200104187B (en) 2002-11-22
GEP20053431B (en) 2005-01-25
EA200300040A1 (ru) 2003-06-26
UA74194C2 (uk) 2005-11-15
CZ2003497A3 (cs) 2004-08-18
AR032756A1 (es) 2003-11-26
TW593223B (en) 2004-06-21
CN1620419A (zh) 2005-05-25
CA2410852C (en) 2007-04-24
NO20026103D0 (no) 2002-12-19
CN1307147C (zh) 2007-03-28
NO329491B1 (no) 2010-10-25
IL153480A (en) 2007-08-19
IL153480A0 (en) 2003-07-06
US20100298442A1 (en) 2010-11-25
EA006067B1 (ru) 2005-08-25
WO2001098253A3 (en) 2002-04-25
US20070105961A1 (en) 2007-05-10
KR20030053475A (ko) 2003-06-28
JP4159351B2 (ja) 2008-10-01
PL359583A1 (en) 2004-08-23
EP1303477A2 (en) 2003-04-23
HK1076276A1 (en) 2006-01-13
HUP0301551A3 (en) 2005-04-28
CA2410852A1 (en) 2001-12-27
MXPA02012244A (es) 2004-09-06
AU8186101A (en) 2002-01-02
JP2004501130A (ja) 2004-01-15
KR100570374B1 (ko) 2006-04-24
NO20026103L (no) 2003-02-19

Similar Documents

Publication Publication Date Title
HUP0301551A2 (hu) 5-HT3 és idegi nikotinsav receptor antagonista 1-amino-alkil-ciklohexán származékok új alkalmazása
HUP0104188A2 (hu) Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
NO305209B1 (no) N-alkyl-2-substituerte ATP-analoger, slike forbindelser til fremstilling av terapeutikum, farmas°ytisk preparat inneholdende slike forbindelser, og deres anvendelse
CY1106166T1 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf.
HUP0401900A2 (hu) 3-Szubsztituált-4-pirimidon-származékok, ezeket tartalmazó gyógyászati készítmények és intermedierjeik
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
PT1158973E (pt) Utilizacao de derivados de sulfamato para o tratamento dos disturbios do controlo de impulsos
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
IS2503B (is) Ný efnasambönd
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
DE60011462D1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
NO20060718L (no) Substituerte tiofoner og deres anvendelse
ATE509910T1 (de) Vitamin d derivate mit einem 22-oxa- oder 22-thia-atom, einer sauer-, ester- oder amid- substitutierten c17-seitenkette und einer 16(17)- doppelbindung
NO20001781L (no) 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
BR0309558A (pt) Derivados de quinazolina e medicamentos
CO4980887A1 (es) Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
SE0101322D0 (sv) Novel compounds
HUP0203275A2 (hu) 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása
NO20055754L (no) Kolkisosidanaloger
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
HUP0301594A2 (hu) E-metanikotin diacilborkősav sóját tartalmazó gyógyászati készítmények és alkalmazásuk a központi idegrendszer rendellenességeinek kezelésére

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees